BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
+20.82%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$2.42B
AUM Growth
+$2.42B
(+17%)
Cap. Flow
+$150M
Cap. Flow
% of AUM
6.2%
Top 10 Holdings %
Top 10 Hldgs %
42.31%
Holding
83
New
4
Increased
11
Reduced
18
Closed
3
Top Buys
| 1 |
Ionis Pharmaceuticals
IONS
|
$70.6M |
| 2 |
THRD
Third Harmonic Bio
THRD
|
$66.4M |
| 3 |
ALLK
Allakos
ALLK
|
$30.6M |
| 4 |
VERV
Verve Therapeutics
VERV
|
$22.3M |
| 5 |
Revolution Medicines
RVMD
|
$19.7M |
Top Sells
| 1 |
Arcus Biosciences
RCUS
|
$32.5M |
| 2 |
Xenon Pharmaceuticals
XENE
|
$25.2M |
| 3 |
EQRX
EQRx, Inc. Common Stock
EQRX
|
$23M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
$13.4M |
| 5 |
Merus
MRUS
|
$12.8M |
Sector Composition
| 1 | Healthcare | 98.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
MoonLake Immunotherapeutics
MLTX
$3.54B
| $173M | 7.15% | 21,751,284 | – | – |
|
|
2
Ionis Pharmaceuticals
IONS
$6.79B
| $127M | 5.25% | 2,872,953 +1,596,379 | +125% | +$70.6M |
|
3
GH Research
GHRS
$837M
| $108M | 4.45% | 9,275,158 | – | – |
|
4
Kymera Therapeutics
KYMR
$2.95B
| $102M | 4.22% | 4,692,604 +553,846 | +13% | +$12.1M |
|
5
Repare Therapeutics
RPTX
$71.7M
| $101M | 4.15% | 8,291,988 | – | – |
|
6
Relay Therapeutics
RLAY
$619M
| $97.1M | 4.01% | 4,339,521 -45,284 | -1% | -$1.01M |
|
7
Cullinan Oncology
CGEM
$445M
| $96.3M | 3.98% | 7,509,059 | – | – |
|
8
Relmada Therapeutics
RLMD
$37.2M
| $76.9M | 3.18% | 2,078,220 +419,000 | +25% | +$15.5M |
|
9
Crinetics Pharmaceuticals
CRNX
$2.92B
| $72.3M | 2.98% | 3,678,947 | – | – |
|
|
10
Arcus Biosciences
RCUS
$1.13B
| $71.1M | 2.94% | 2,717,020 -1,243,928 | -31% | -$32.5M |
|
|
11
Merus
MRUS
$4.98B
| $69M | 2.85% | 3,444,420 -637,011 | -16% | -$12.8M |
|
|
THRD
12
DELISTED
Third Harmonic Bio
THRD
| $66.4M | 2.74% | +3,501,814 | New | +$66.4M |
|
13
Xoma
XOMA
$392M
| $64.7M | 2.67% | 3,611,494 +80,951 | +2% | +$1.45M |
|
|
14
Revolution Medicines
RVMD
$7.1B
| $64.2M | 2.65% | 3,255,588 +1,000,000 | +44% | +$19.7M |
|
15
Aclaris Therapeutics
ACRS
$209M
| $62.6M | 2.59% | 3,976,543 | – | – |
|
|
CTIC
16
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $51.3M | 2.12% | 8,813,021 -116,669 | -1% | -$679K |
|
17
IDEAYA Biosciences
IDYA
$2.15B
| $49.2M | 2.03% | 3,294,859 +500,000 | +18% | +$7.46M |
|
18
Kura Oncology
KURA
$686M
| $43.8M | 1.81% | 3,203,783 | – | – |
|
|
PNT
19
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $43.2M | 1.79% | 5,590,048 +2,222,222 | +66% | +$17.2M |
|
|
20
Syndax Pharmaceuticals
SNDX
$1.41B
| $43.2M | 1.78% | 1,798,085 -558,849 | -24% | -$13.4M |
|
|
CINC
21
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $43.1M | 1.78% | 1,312,443 -331,950 | -20% | -$10.9M |
|
22
Lexicon Pharmaceuticals
LXRX
$400M
| $38.8M | 1.6% | 16,149,179 +2,000,000 | +14% | +$4.8M |
|
23
Viridian Therapeutics
VRDN
$1.5B
| $35.7M | 1.48% | 1,741,840 -2,172 | -0.1% | -$44.5K |
|
24
iTeos Therapeutics
ITOS
| $34.5M | 1.43% | 1,810,835 -118,366 | -6% | -$2.25M |
|
|
25
Xenon Pharmaceuticals
XENE
$2.98B
| $32.5M | 1.34% | 901,095 -696,871 | -44% | -$25.2M |
|